figshare
Browse
nncs_a_1506039_sm7048.docx (23.17 kB)

Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia

Download (23.17 kB)
journal contribution
posted on 2018-08-16, 11:58 authored by Ione O.C. Woollacott, Martina Bocchetta, Carole H. Sudre, Basil H. Ridha, Catherine Strand, Robert Courtney, Sebastien Ourselin, M. Jorge Cardoso, Jason D. Warren, Martin N. Rossor, Tamas Revesz, Nick C. Fox, Janice L. Holton, Tammaryn Lashley, Jonathan D. Rohrer

White matter hyperintensities (WMH) are often seen on MRI brain scans in frontotemporal dementia (FTD) due to progranulin (GRN) mutations, but their pathological correlates are unknown. We examined the histological changes underlying WMH in a patient with GRN mutation associated behavioral variant FTD. In vivo and cadaveric MRI showed progressive, asymmetric frontotemporal and parietal atrophy, and asymmetrical WMH predominantly affecting frontal mid-zones. We first performed segmentation and localization analyses of WMH present on cadaveric MRI FLAIR images, then selected five different brain regions directly matched to differing severities of WMH for histological analysis. We used immunohistochemistry to assess vascular pathology, degree of spongiosis, neuronal and axonal loss, TDP-43, demyelination and astrogliosis, and microglial burden and morphology. Brain regions with significant WMH displayed severe cortical and white matter pathology, and prominent white matter microglial activation and microglial dystrophy, but only mild axonal loss and minimal vascular pathology. Our study suggests that WMH in GRN mutation carriers are not secondary to vascular pathology. Whilst cortical pathology induced axonal degeneration could contribute to white matter damage, individuals with GRN mutations could develop selective white matter vulnerability and myelin loss due to chronic, regional microglial dysfunction arising from GRN haploinsufficiency.

Funding

This work was funded by the Medical Research Council UK. The Dementia Research Centre is an Alzheimer’s Research UK coordinating centre and is supported by Alzheimer’s Research UK, the Brain Research Trust and the Wolfson Foundation. Queen Square Brain Bank is supported by the Reta Lila Weston Institute for Neurological Studies, the Progressive Supranuclear Palsy (Europe) Association and the Medical Research Council UK. IOCW is funded by a Medical Research Council Clinical Research Training Fellowship (MR/M018288/1). JDW has received funding support from the Alzheimer’s Society. JLH is supported by the Multiple System Atrophy Trust; the Multiple System Atrophy Coalition; Fund Sophia, managed by the King Baudouin Foundation; Alzheimer’s Research UK and CBD Solutions. JDR is a Medical Research Council Clinician Scientist (MR/M008525/1) and has received funding from the National Institute for Health Research Rare Diseases Translational Research Collaboration (BRC149/NS/MH), the Bluefield Project and the Association for Frontotemporal Degeneration. TL is funded by an Alzheimer’s Research UK Senior Fellowship.

History